Roche has signed a development and collaboration agreement with Novo Nordisk, a leader in innovating the therapy of diabetes and obesity. Under the terms of the development and collaboration agreement, the partners will integrate insulin data from Novo Nordisk’s connected pen to Roche’s open ecosystem, synchronizing with its suite of digital diabetes management solutions including mySugr.
People with diabetes spend an average of one hour per day on self-care and have to make up to 50 therapy decisions daily. Digital health solutions have the potential to ease this constant burden and as such to support better therapy adherence and improved outcomes.
“We believe in the tremendous benefits integrated digital diabetes management solutions can bring to people with diabetes, caregivers and healthcare systems as part of an open ecosystem and are excited to partner with Novo Nordisk to further drive innovation in this area,” says Marcel Gmuender, Global Head of Roche Diabetes Care. “The integration of insulin pen data in our digital health solutions such as mySugr will make it much easier for people with diabetes and their caregivers to track the effect of insulin on blood glucose levels. This enables more efficient and targeted decision support, as they can act on near real-time insights to optimize the personalized diabetes management thereby reducing the risk of costly secondary complications and contributing to improved therapy outcomes and better quality of life.”